Thomas Alexandra, Khan Seema A, Chrischilles Elizabeth A, Schroeder Mary C
Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City.
Division of Breast Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
JAMA Surg. 2016 May 1;151(5):424-31. doi: 10.1001/jamasurg.2015.4539.
Management of the primary tumor site in patients with metastatic breast cancer remains controversial.
To evaluate the patterns of receipt of initial breast surgery for female patients with stage IV breast cancer in the United States, with particular attention to women who survived at least 10 years.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study using data from the Surveillance, Epidemiology, and End Results (SEER) program. Female patients diagnosed as having stage IV breast cancer between 1988 and 2011 and who did not receive radiation therapy as part of the first course of treatment were included (N = 21 372). Kaplan-Meier estimates of median survival and descriptive statistics were used to compare patient and tumor characteristics by receipt of breast surgery at diagnosis. A Royston-Parmar survival model and logistic regression analysis assessed demographic and clinical factors associated with survival and prolonged survival (of at least 10 years).
Differences in survival, particularly survival of at least 10 years, by receipt of initial surgery to the primary tumor.
Among the 21 372 patients, the median survival increased from 20 months (1988-1991) to 26 months (2007-2011). During this time, the rate of surgery declined (odds ratio [OR], 0.16; 95% CI, 0.12-0.21). Even so, receipt of surgery was associated with improved survival in multivariate analysis, which controlled for patient and clinical characteristics, along with time period (hazard ratio, 0.60; 95% CI, 0.57-0.63). For women diagnosed as having cancer before 2002 (n = 7504), survival of at least 10 years was seen in 9.6% (n = 353) and 2.9% (n = 107) of those who did and did not receive surgery, respectively (OR, 3.61; 95% CI, 2.89-4.50). In multivariate analysis, survival of at least 10 years was associated with receipt of surgery (odds ratio, 2.80; 95% CI, 2.08-3.77), hormone receptor-positive disease (OR, 1.76; 95% CI, 1.25-2.48), older age (OR, 0.41; 95% CI, 0.32-0.54), larger tumor size (OR, 0.37; 95% CI, 0.27-0.51), marital status of being separated at the time of diagnosis (OR, 0.67; 95% CI, 0.51-0.88), and more recent year of diagnosis (OR, 1.43; 95% CI, 1.02-1.99).
Survival in stage IV breast cancer has improved and is increasingly of prolonged duration, particularly for some women undergoing initial breast surgery. As systemic therapy advances provide better control of distant disease in stage IV breast cancer, and as women present with lower distant disease burdens, these findings on initial surgery to the primary tumor may be of importance.
转移性乳腺癌患者原发肿瘤部位的管理仍存在争议。
评估美国IV期乳腺癌女性患者接受初次乳房手术的模式,尤其关注存活至少10年的女性。
设计、设置和参与者:一项回顾性队列研究,使用监测、流行病学和最终结果(SEER)计划的数据。纳入1988年至2011年间被诊断为IV期乳腺癌且未接受放射治疗作为首个疗程一部分的女性患者(N = 21372)。采用Kaplan-Meier法估计中位生存期,并使用描述性统计按诊断时是否接受乳房手术比较患者和肿瘤特征。采用Royston-Parmar生存模型和逻辑回归分析评估与生存及长期生存(至少10年)相关的人口统计学和临床因素。
接受初次原发肿瘤手术与否在生存方面的差异,尤其是至少存活10年的情况。
在21372例患者中,中位生存期从1988 - 1991年的20个月增加到2007 - 2011年的26个月。在此期间,手术率下降(优势比[OR],0.16;95%置信区间,0.12 - 0.21)。即便如此,在多变量分析中,控制了患者和临床特征以及时间段后,接受手术与生存改善相关(风险比,0.60;95%置信区间,0.57 - 0.63)。对于2002年前被诊断为癌症的女性(n = 7504),接受手术和未接受手术的患者中分别有9.6%(n = 353)和2.9%(n = 107)存活至少10年(OR,3.61;95%置信区间,2.